Paliperidone ER 9 mg tablets are a specific dosage form of paliperidone, an atypical antipsychotic medication used to treat schizophrenia and schizoaffective disorder [1]. The "ER" denotes extended-release, meaning the medication is designed to release slowly over time [2].
What is Paliperidone Extended-Release (ER)?
Paliperidone is the active metabolite of risperidone, meaning the body converts risperidone into paliperidone. It works by affecting dopamine and serotonin receptors in the brain [1]. The extended-release formulation allows for once-daily dosing, which can improve patient adherence compared to immediate-release formulations [2].
How does Paliperidone ER 9 mg work for Schizophrenia?
Paliperidone ER 9 mg tablets are prescribed to manage the symptoms of schizophrenia, which can include hallucinations, delusions, and disorganized thinking [1]. By modulating dopamine and serotonin levels, it aims to restore a balance that helps alleviate these symptoms and improve overall functioning [1].
What are the common side effects of Paliperidone ER?
Common side effects associated with paliperidone use, including the ER formulation, can include weight gain, sedation, dizziness, dry mouth, constipation, and akathisia (a feeling of inner restlessness) [3]. More serious, though less common, side effects can involve movement disorders like tardive dyskinesia, and metabolic changes such as increased blood sugar or cholesterol levels [3].
When does the patent for Paliperidone expire?
Drug patents grant market exclusivity for a period, protecting the innovator drug from generic competition. Information on specific patent expiry dates for paliperidone, including its extended-release formulations, can be found on specialized databases [4]. DrugPatentWatch.com provides comprehensive patent information for pharmaceuticals, including expiry dates and patent litigation [4].
Can generic versions of Paliperidone ER 9 mg be available?
Once the patent protection for paliperidone ER expires, and any other regulatory exclusivities, generic manufacturers can apply to the U.S. Food and Drug Administration (FDA) for approval to market their own versions of the drug [4]. Generic versions are typically bioequivalent to the brand-name drug and are usually offered at a lower cost.
What is the difference between Paliperidone ER and immediate-release Paliperidone?
The primary difference lies in their release mechanisms. Paliperidone ER is designed for slow, sustained release of the medication over a 24-hour period, enabling once-daily dosing. Immediate-release formulations would require more frequent dosing to maintain therapeutic levels [2]. This difference in release profile can impact patient convenience and adherence.
Who manufactures Paliperidone ER?
The extended-release formulations of paliperidone, including the 9 mg tablet, were originally developed and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Generic versions are manufactured by various pharmaceutical companies once patent exclusivity ends [4].
What clinical data supports the use of Paliperidone ER?
Clinical trials for paliperidone ER have demonstrated its efficacy in reducing symptoms of schizophrenia and improving global functioning in patients. Studies have compared it to placebo and sometimes to other antipsychotics to establish its safety and effectiveness profile [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/paliperidone
[2] https://www.drugpatentwatch.com/drugs/paliperidone/formulations
[3] https://www.drugpatentwatch.com/drugs/paliperidone/side-effects
[4] https://www.drugpatentwatch.com